SAN DIEGO - Sept. 3, 2020 - Dr. Edward Strong, the geneticist who co-founded and served as CEO of MedGenomics, Inc., has been named Scientific Director of iAssay, Inc. Strong will guide the researchers and engineers who are developing iAssay's product line.
iAssay is creating tools that support remote testing for COVID-19 and other medical conditions directly from patients' homes, physicians' offices, workplaces, and other locations. The data gathered by an iAssay device is uploaded to the Cloud, and instantly becomes available for evaluation by physicians and clinicians.
"iAssay is committed to empowering rapid, secure, accurate diagnostics, delivered from any remote location," Strong said. "This will greatly increase access to healthcare for all Americans, including the homebound and other underserved populations."
Strong holds a Ph.D from Cornell University. He is a former NIH Fellow who contributed to work that won awards from the National Cancer Institute and the National Institute of Child Health and Human Development. Strong has translated scientific breakthroughs into meaningful products throughout his career.
At MedGenomics, Inc., Strong helped consumers understand the real-world implications of genetic tests. Recently, as interim CEO of LifeGenomix, Inc., his team repurposed genetic testing capabilities originally designed for human athletic performance for use in non-human markets. In so doing, he was able to demonstrate proof of concept to support equine purchasing and training decisions. LifeGenomix's system was designed to create smarter, healthier, and more responsible breeding and veterinary care programs.
"Ed is a rare individual, combining world-class intelligence with a burning desire to help others," said Lonnie Adelman, founder and CEO of iAssay, Inc. "He'll lead a team that is passionate about meeting the ever-increasing health care needs of a diverse population."
iAssay's hand-held device serves multiple purposes. Lightweight and portable, it can be used by healthcare providers to analyze a patient sample of blood, urine, or saliva, then relay key diagnostic information to the Cloud.
Dr. Strong summed it up, "iAssay is mission-driven to enable faster, more accurate POC diagnostics, and has the incredible engineering and product development team necessary. I am thrilled to join the team and look forward to building and executing on our opportunities together with the growing number of rapid diagnostic assays."
i———————————————
About iAssay
The patented iAssay® System is the world's first open platform for wirelessly-connected point of care diagnostics testing in minutes. iAssay's handheld device can interpret a multitude of Cleared POC tests while managing the data: It eliminates patient sample transportation, reduces human error by automatically interpreting tests with the assistance of AI, automatically saves test results in the Cloud, consolidates all available POC tests onto a single Reader, and aggregates test results from other test equipment . http://iassay.net/
Contact
Lonnie Adelman, Founder and CEO
